About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants |
| |
| Authors: | Sara Gutiérrez‐Enríquez Sandra Bonache Gorka Ruíz de Garibay Ana Osorio Marta Santamariña Teresa Ramón y Cajal Eva Esteban‐Cardeñosa Anna Tenés Kira Yanowsky Alicia Barroso Gemma Montalban Ana Blanco Mònica Cornet Neus Gadea Mar Infante Trinidad Caldés Eduardo Díaz‐Rubio Judith Balmaña Adriana Lasa Ana Vega Javier Benítez Miguel de la Hoya Orland Diez |
| |
| Affiliation: | 1. Oncogenetics Group Vall d'Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain;2. Oncogenetics Group, Vall d'Hebron Research Institute (VHIR) and Universitat Autonoma de Barcelona, Barcelona, Spain;3. Laboratorio de Oncología Molecular, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain;4. Human Genetics Group Human Cancer Genetics Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain;5. Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain;6. Grupo de Medicina Xenómica‐USC, University of Santiago de Compostela, CIBERER, IDIS, Santiago de Compostela, Spain;7. Medical Oncology Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain;8. Instituto de Biología y Genética Molecular (UVa‐CSIC), Genética del Cáncer, Valladolid, Spain;9. Fundación Pública Galega de Medicina Xenómica‐SERGAS, Grupo de Medicina Xenómica, CIBERER, IDIS, Santiago de Compostela, Spain;10. Genetics Department, CIBERER U‐705, Santa Creu i Sant Pau Hospital, Barcelona, Spain;11. Medical Oncology Department, University Hospital of Vall d'Hebron, Barcelona, Spain;12. Servicio de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain;13. Medical Oncology Department, University Hospital of Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain;14. Oncogenetics Group, University Hospital of Vall d'Hebron, Barcelona, Spain |
| |
| Abstract: | RAD51D mutations have been recently identified in breast (BC) and ovarian cancer (OC) families. Although an etiological role in OC appears to be present, the association of RAD51D mutations and BC risk is more unclear. We aimed to determine the prevalence of germline RAD51D mutations in Spanish BC/OC families negative for BRCA1/BRCA2 mutations. We analyzed 842 index patients: 491 from BC/OC families, 171 BC families, 51 OC families and 129 patients without family history but with early‐onset BC or OC or metachronous BC and OC. Mutation detection was performed with high‐resolution melting, denaturing high‐performance liquid chromatography or Sanger sequencing. Three mutations were found in four families with BC and OC cases (0.82%). Two were novel: c.1A>T (p.Met1?) and c.667+2_667+23del, leading to the exon 7 skipping and one previously described: c.674C>T (p.Arg232*). All were present in BC/OC families with only one OC. The c.667+2_667+23del cosegregated in the family with one early‐onset BC and two bilateral BC cases. We also identified the c.629C>T (p.Ala210Val) variant, which was predicted in silico to be potentially pathogenic. About 1% of the BC and OC Spanish families negative for BRCA1/BRCA2 are carriers of RAD51D mutations. The presence of several BC mutation carriers, albeit in the context of familial OC, suggests an increased risk for BC, which should be taken into account in the follow‐up and early detection measures. RAD51D testing should be considered in clinical setting for families with BC and OC, irrespective of the number of OC cases in the family. |
| |
| Keywords: | RAD51D genetic predisposition familial breast and ovarian cancer |
|
|
